| Literature DB >> 23259907 |
Thomas Weig1, Mirjam I Schubert, Norbert Gruener, Michael E Dolch, Lorenz Frey, Jens Miller, Thorsten Johnson, Michael Irlbeck.
Abstract
BACKGROUND: Secondary sclerosing cholangitis is a severe disease of the biliary tract. Over the last decade, several cases of sclerosing cholangitis in critically ill patients (SC-CIP) were reported. Reports in the literature so far are characterized by a wide variety of underlying causes of critical illness, thereby hindering a risk-factor analysis. We report on a homogenous cohort of critically ill patients with influenza A (H1N1) pneumonia and severe acute respiratory distress syndrome (ARDS), of whom a subgroup developed sclerosing cholangitis, allowing for probing of risk factors associated with SC-CIP.Entities:
Mesh:
Year: 2012 PMID: 23259907 PMCID: PMC3543205 DOI: 10.1186/2047-783X-17-30
Source DB: PubMed Journal: Eur J Med Res ISSN: 0949-2321 Impact factor: 2.175
Clinical characteristics on admission day
| Age (years) | 46.3 ± 10.8 | 46.4 ± 9.7 | 46.2 ± 11.4 | NS |
| Sex | | | | |
| Male | 16 | 5 | 11 | |
| Female | 5 | 0 | 5 | |
| Height (cm) | 177.6 ± 8.3 | 180.0 ± 3.5 | 176.5 ± 9.5 | NS |
| Weight (kg) | 98.4 ± 22.7 | 120.8 ± 18.1 | 91.4 ± 20.1 | <0.01 |
| BMI (kg/m2) | 31.2 ± 7.4 | 37.4 ± 6.0 | 29.6 ± 7.0 | 0.03 |
| BSA (m2) | 2.2 ± 0.3 | 2.5 ± 0.2 | 2.1 ± 0.2 | <0.01 |
| SAPS IIa | 40.4 ± 9.2 | 43.4 ± 10.2 | 39.7 ± 9.3 | NS |
| SOFA* | 12.8 ± 1.9 | 14.0 ± 0 | 12.4 ± 2.2 | NS |
| Murray | 3.5 ± 0.2 | 3.6 ± 0.3 | 3.5 ± 0.2 | NS |
| PaO2/FiO2 | 90.0 ± 37.9 | 93.9 ± 44.5 | 90.6 ± 37.7 | NS |
| PEEP (cmH2O) | 16.3 ± 2.4 | 17.6 ± 2.9 | 16.0 ± 2.2 | NS |
| Peak inspiratory pressure (cmH2O) | 30.0 ± 4.3 | 32.0 ± 6.5 | 29.1 ± 3.4 | NS |
| Lung compliance (l/cmH2O) | 33.8 ± 11.5 | 40.2 ± 19.8 | 31.2 ± 7.2 | NS |
| Ventilation before admission (days) | 2.8 ± 3.2 | 2.8 ± 3.3 | 3.0 ± 3.3 | NS |
aThe Glasgow Coma Scale (GCS) score was not included, since all patients had been intubated and sedated on admission; data for GCS before intubation were not available. BMI, body mass index; BSA, body surface area; NS, non-significant; nSSC, no secondary sclerosing cholangitis; PaO2/FiO2, partial arterial oxygen pressure/inspired oxygen concentration ratio; SAPS II, New Simplified Acute Physiology Score; SSC, secondary sclerosing cholangitis; SOFA, sequential organ failure assessment.
Clinical course
| Total duration of ventilation (days) | 30.1 ± 48.4 | 88.2 ± 76.4 | 11.9 ± 9.2 | <0.01 |
| Total days in ICU | 39.6 ± 46.1 | 89.2 ± 75.5 | 30.1 ± 15.2 | <0.01 |
| ECMO | | | | |
| Patients treated (%) | 10 (47.6%) | 3 (60%) | 7 (43.8%) | NS |
| Duration of ECMO (days) | 27.3 ± 20 | 45.7 ± 26 | 19.4 ± 11.5 | 0.05 |
| Survival (%) | 15 (71.4%) | 0 (0%) | 15 (93.8%) | <0.01 |
| Patients requiring RRT during ICU treatment from day 1 to 28 (%) | 10 (47.6%) | 4 (80%) | 6 (37.5%) | NS |
| Patients receiving stress-dose steroids (%) | 14 (66.7%) | 5 (100%) | 9 (56.3%) | <0.01 |
| Mean dosage of norepinephrine day 1 to 7 (μg(kg min)) | 0.13 ± 0.12 | 0.15 ± 0.12 | 0.12 ± 0.11 | NS |
ECMO, extracorporeal membrane oxygenation; NS, non-significant; nSSC, no secondary sclerosing cholangitis; RRT, renal replacement therapy; SSC, secondary sclerosing cholangitis.
Figure 1Cumulative time of pronation in patients without (nSSC) and with (SSC) secondary cholangitis. * indicates significant difference (P = 0.04).
Figure 2Ventilator settings and respiratory function indicated by peak inspiratory pressure (PIP), positive end-expiratory pressure (PEEP) and ratio of partial arterial oxygen pressure to the fraction of inspired oxygen (PaO * indicates significant difference (P < 0.001).
Figure 3Temporal course of alkaline phosphatase (AP), γ-glutamyl transpeptidase (GGT) and total serum bilirubin levels in patients without (nSSC) and with (SSC) secondary cholangitis. * indicates significant difference (P = 0.001).
Parameters derived from multi-detector computed tomography analysis
| Abdominal diameter, sagittal (cm) | 28.0 ± 4.7 | 32.3 ± 4.3 | 26.6 ± 4.0 | 0.015 |
| Intraperitoneal diameter, horizontal (cm) | 28.3 ± 3.7 | 32.3 ± 4.1 | 27.0 ± 2.5 | 0.003 |
| Cumulative abdominal fat (cm3) | 17317 ± 8683 | 23677 ± 13759 | 15197 ± 5382 | 0.056 |
| Intraperitoneal fat (cm3) | 5916 ± 2926 | 8273 ± 3659 | 5131 ± 2268 | 0.033 |
| Intraperitoneal fat / height (cm3/cm) | 33.3 ± 16.1 | 46.0 ± 20.3 | 29.0 ± 12.4 | 0.036 |
| Subcutaneous fat (cm3) | 11401 ± 6284 | 15404 ± 10261 | 10067 ± 3986 | NS |
| Diameter of common hepatic artery (cm) | 0.65 ± 0.1 | 0.65 ± 0.11 | 0.65 ± 0.1 | NS |
| Diameter of portal vein (cm) | 1.4 ± 0.2 | 1.5 ± 0.3 | 1.4 ± 0.1 | NS |
| Diameter of inferior vena cava (cm) | 2.7 ± 0.3 | 2.9 ± 0.4 | 2.7 ± 0.3 | NS |
| Arthrosclerosis (n) | 7 (37%) | 2 (40%) | 5 (34%) | NS |
| Calcification of celiac trunk (n) | 3 (16%) | 0 (0%) | 3 (20%) | NS |
| Ascites (n) | 9 (47%) | 2 (40%) | 7 (47%) | NS |
NS, non-significant; nSSC, no secondary sclerosing cholangitis; SSC, secondary sclerosing cholangitis.
Primary or underlying diseases in previously described critically ill patients with sclerosing cholangitis
| Severe trauma [ | 16 |
| Burns [ | 11 |
| Extrahepatic bacterial infection [ | 3 |
| Major non-cardiac surgery [ | 8 |
| Cardiac surgery [ | 10 |
| Power current injury [ | 1 |
| Intracerebral hemorrhage [ | 3 |
| Critical illness without specification [ | 26 |